CERVOMED INC. - COMMON STOCK

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 Jul 2024 08:51:12 By Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Appoint William Elder as Chief Financial Officer

20 May 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the BIO CEO and Investor Conference

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire